- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05008198
Assessing an EEG Biomarker of Response to TMS for Major Depression
August 10, 2023 updated by: VA Office of Research and Development
Assessing an Electroencephalography (EEG) Biomarker of Response to Transcranial Magnetic Stimulation for Major Depression
Veterans with treatment resistant depression (TRD) have the opportunity to receive transcranial magnetic stimulation (TMS) treatment via the VA's National TMS Clinical Pilot Program.
While some see improvement with their depression, others do not.
Therefore, it may be beneficial to be able to predict with biomarkers what participants may see improvement with their treatment.
Electroencephalography (EEG) is a means to identify such biomarkers.
Four hundred Veterans with TRD will be enrolled in this trial to determine whether neuroimaging biomarkers of repetitive transcranial magnetic stimulation (TMS) can be prospectively replicated in a large ecologically valid sample.
Participants will have a total of EEG scans at baseline, every 5th treatment session, and at the end of treatment for a total of 7 EEG scans.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The goals of this study are to: (1) test a potential predictive resting EEG biomarker of antidepressant response (differential patters of gamma oscillations) in a large sample of Veterans with TRD receiving TMS (N=400); (2) assess whether a second putative biomarker (early changes in theta cordance during treatment) predict eventual response to TMS, as well as, leverage this large sample to identify other potential biomarkers (such as markers of early versus late response to TMS, markers of response to other TMS parameters (e.g., 5 Hz, 1 Hz or theta burst TMS), and markers of change with treatment that may speak to mechanism); and (3) create an infrastructure to rapidly identify and test additional EEG-based biomarkers of treatment response in patients with depression and other psychiatric conditions.
Study Type
Observational
Enrollment (Estimated)
600
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Paul Holtzheimer, MD
- Phone Number: 6042 (802) 295-9363
- Email: Paul.Holtzheimer@va.gov
Study Contact Backup
- Name: Techieh Chen
- Phone Number: 6995 (802) 295-9363
- Email: Techieh.Chen@va.gov
Study Locations
-
-
Vermont
-
White River Junction, Vermont, United States, 05001-3833
- Recruiting
- White River Junction VA Medical Center, White River Junction, VT
-
Contact:
- Paul Holtzheimer, MD
- Phone Number: 6042 802-295-9363
- Email: Paul.Holtzheimer@va.gov
-
Principal Investigator:
- Paul Holtzheimer, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Veterans with major depressive disorder (MDD) participating in the VA Clinical TMS Pilot Program.
Given the complex nature of the Veteran population, the primary diagnosis of MDD may be comorbid with other disorders, including post-traumatic stress disorder (PTSD).
Description
Inclusion Criteria:
- Veterans participating in the VA TMS Pilot Program age 18 years or older
- Able to provide written informed consent to participate in the EEG portion of this study and to allow linking such data to data collected as part of the TMS Pilot Program
- Diagnosis of MDD based on DSM-5 criteria and be currently depressed despite prior treatment with at least one adequate antidepressant treatment
- Receiving stable doses of psychiatric medications (no dose changes for >4 weeks prior to study entry), in stable psychotherapy, or receiving no psychiatric medications and/or psychotherapy
Exclusion Criteria:
- History of seizure disorder
- Known structural or neurologic abnormalities present or close to the treatment site that would increase risk of seizure
- History of brain surgery
- History of recent traumatic brain injury (within 6 months) or any history of moderate to severe traumatic brain injury
- Clinical evidence of severe or uncontrolled alcohol or substance use disorders within three months
- Active withdrawal from alcohol or other substances of abuse
- Implanted metal device in the head that would increase the risk of TMS
- Metal in the head that would increase the risk of TMS
- Current psychosis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Transcranial Magnetic Stimulation
Transcranial Magnetic Stimulation is delivered as part of routine care and is not managed by this observational study.
|
Transcranial Magnetic Stimulation is delivered as part of routine care and is not managed by this observational study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Inventory of Depressive Symptomatology-Self Report (IDS-SR)
Time Frame: 1) Baseline, pre-treatment and 2) 6 weeks, treatment completion
|
The IDS-SR is a 30-item self-report depressive symptom severity rating scale.
The IDS-SR has been shown to have highly acceptable psychometric properties and has been found to be a treatment sensitive measures of symptom severity in depression.
Each question is on a scale of 0 to 4. The IDS-SR has a score range between 0 to 84, with a higher score reflecting higher symptom severity in depression.
|
1) Baseline, pre-treatment and 2) 6 weeks, treatment completion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Paul Holtzheimer, MD, White River Junction VA Medical Center, White River Junction, VT
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 19, 2021
Primary Completion (Estimated)
September 30, 2025
Study Completion (Estimated)
September 30, 2026
Study Registration Dates
First Submitted
July 30, 2021
First Submitted That Met QC Criteria
August 9, 2021
First Posted (Actual)
August 17, 2021
Study Record Updates
Last Update Posted (Actual)
August 15, 2023
Last Update Submitted That Met QC Criteria
August 10, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSDR-001-19S
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on Transcranial Magnetic Stimulation
-
State University of New York - Upstate Medical...RecruitingHeadache | Brain Concussion | Mild Traumatic Brain Injury | Post-Concussion SymptomsUnited States
-
George Mason UniversityMedStar National Rehabilitation NetworkCompletedStroke | Stroke, Ischemic | Hemiparesis | Cerebral Vascular AccidentUnited States
-
Russian Academy of Medical SciencesCompletedStrokeRussian Federation
-
Centre hospitalier de l'Université de Montréal...Canadian Institutes of Health Research (CIHR)RecruitingMajor Depressive DisorderCanada
-
University Hospital TuebingenFederal Ministry of Health, Germany; University of Ulm; Department of Psychiatry... and other collaboratorsRecruitingMajor Depressive DisorderGermany
-
VA Office of Research and DevelopmentRecruitingDepression | Gulf War IllnessUnited States
-
National Institute of Mental Health (NIMH)CompletedHealthy VolunteersUnited States
-
University of ManitobaManitoba Medical Service FoundationSuspendedObsessive Compulsive DisorderCanada
-
Beth Israel Deaconess Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Brigham and Women's HospitalNot yet recruitingAnxiety Disorders | Psychiatric Disorder | Mental DisorderUnited States